0001193125-24-257205.txt : 20241113 0001193125-24-257205.hdr.sgml : 20241113 20241113161031 ACCESSION NUMBER: 0001193125-24-257205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241113 DATE AS OF CHANGE: 20241113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 241454265 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 8-K 1 d877348d8k.htm 8-K 8-K
false 0001806310 0001806310 2024-11-13 2024-11-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2024

 

 

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware   001-39536   84-3199512

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3000 Pegasus Park Drive, Suite 1430

Dallas, Texas

   75247
(Address of Principal Executive Offices)   (Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.00001 par value   TSHA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On November 13, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press Release, dated November 13, 2024.
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Taysha Gene Therapies, Inc.
Dated: November 13, 2024     By:  

/s/ Kamran Alam

      Kamran Alam
      Chief Financial Officer
 EX-99.1 2 d877348dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4)

Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development plan for TSHA-102 following initial RMAT Type B meeting

FDA approved use of pivotal TSHA-102 product in REVEAL trials based on successful demonstration of analytical comparability; Company released pivotal product manufactured with the final commercial manufacturing process following Type D CMC meeting

Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025

Conference call and live webcast today at 4:30 PM Eastern Time

Dallas – November 13, 2024 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.

“We are pleased with the progress made with the FDA on further elucidating the potential regulatory pathway for TSHA-102 as we advanced discussions on the trial design, endpoints and potential use of an established natural history dataset for Part B of our REVEAL trials. Additionally, we aligned on a meeting cadence to expedite the development plan for TSHA-102,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “We are in a strong position with CMC, having obtained FDA approval to use the pivotal product in our REVEAL trials based on the successful demonstration of analytical comparability. Subsequently, we released the pivotal product manufactured with the final commercial manufacturing process that we intend to use in Part B.”

Mr. Nolan continued, “Clinical data presented from the adult patients with the most advanced stage of the disease treated with the low dose of TSHA-102 indicate a pattern of early clinical improvements and functional gains across multiple domains within four weeks post-treatment that persisted and strengthened over time. As the pediatric data mature, we anticipate that the early clinical improvements and functional gains observed should also persist and strengthen over time in the pediatric patients treated with TSHA-102. We look forward to reporting longer-term data from the low dose cohort and data from the high dose cohort of both REVEAL trials in the first half of 2025. We plan to continue working closely with the FDA through the RMAT mechanism to solidify the regulatory pathway for TSHA-102 based on the totality of data and remain focused on execution as we prepare for what we expect to be an impactful year ahead.”

Recent Corporate and TSHA-102 Program Highlights

 

  •  

Completed Regenerative Medicine Advanced Therapy (RMAT) Type B Meeting. Advanced discussions on regulatory pathway for TSHA-102 following initial RMAT Type B multidisciplinary meeting with the United States (U.S.) Food and Drug Administration (FDA)

 

  •  

Advanced discussions with the FDA on trial design, endpoints and potential use of an established natural history dataset for Part B of the REVEAL Phase 1/2 trials

 

  •  

Based on FDA feedback from ongoing discussions, the Company intends to focus on objective measures that clinically capture functional gains; the Rett Syndrome Behavior Questionnaire (RSBQ) will not be included as a primary or secondary endpoint in Part B of the REVEAL trials

 

  •  

Aligned with the FDA on the Company’s proposed meeting cadence to expedite the development and review of TSHA-102 and on the adequacy of the nonclinical data package submitted to date to support Biologics License Application submission

 

  •  

Reached FDA Alignment on Commercial Manufacturing Process. Completed Type D Chemistry Manufacturing and Controls (CMC) meeting with the FDA regarding TSHA-102

 

  •  

The FDA approved use of the pivotal product in the REVEAL trials based on the successful demonstration of analytical comparability between the clinical product and the product derived from the final commercial manufacturing process

 

  •  

The Company released the pivotal product manufactured with the final commercial manufacturing process for use in Part B of the REVEAL Phase 1/2 trials

 

  •  

The FDA endorsed the intended commercial manufacturing process, proposed analytical methods, and corresponding qualification and validation plans, including mechanism of action potency release assays

 

  •  

High Dose of TSHA-102 was Generally Well Tolerated. TSHA-102 was generally well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) in the first two adolescent/adult patients as of 20 and nine weeks, respectively, and in the first pediatric patient as of six weeks

 

  •  

Continued Enrollment in High Dose Cohorts. Received Independent Data Monitoring Committee (IDMC) approval to continue with enrollment in cohort two (high dose, 1x1015 total vector genomes (vg)) across both REVEAL Phase 1/2 trials, following review of available clinical data from the first two adolescent/adult patients and the first pediatric patient treated with the high dose of TSHA-102

 

  •  

Dosed the third adolescent/adult patient in cohort two and enrolled the second pediatric patient in cohort two, with dosing scheduled for the current quarter

 

  •  

Presented Positive Previously Disclosed Clinical Data on Low Dose TSHA-102. Clinical data from cohort one (low dose, 5.7x1014 total vg) in both the ongoing REVEAL Phase 1/2 adolescent/adult trial and the REVEAL Phase 1/2 pediatric trial were presented during an oral presentation at the 9th World Rett Syndrome Congress in October 2024

 

  •  

Adolescent/Adult Trial (n=2):

 

  •  

Generally well tolerated with no SAEs related to TSHA-102 or DLTs as of 52 and 36 weeks for patient one and two, respectively

 

  •  

Early and consistent clinical improvements and functional gains demonstrated across multiple clinical domains (fine and gross motor skills, communication/socialization, autonomic function and seizure events) as early as four weeks post-treatment, with sustained and new improvements through 52- and 25-weeks post-treatment for patient one and two, respectively, based on clinician and caregiver assessments and video evidence

 

  •  

Pediatric Trial (n=2):

 

  •  

Generally well tolerated with no SAEs related to TSHA-102 or DLTs as of 22 and 11 weeks for patient one and two, respectively

  •  

Early and consistent clinical improvements and functional gains demonstrated across multiple clinical domains (fine and gross motor skills, communication/socialization, autonomic function and seizure events) as early as four weeks post-treatment, with sustained and new improvements through 12- and eight-weeks post-treatment for patient one and two, respectively, based on clinician and caregiver assessments and video evidence

 

  •  

Presented Biodistribution Data Further Supporting the Clinical Potential of Intrathecal Delivery. Data from an analysis of 28 non-human primates (NHP) across five studies evaluating AAV9 gene therapy delivery were presented during a poster presentation at the 31st Annual Congress of the European Society of Gene & Cell Therapy in October 2024

 

  •  

Both intrathecal and intra-cisterna magna administration showed comparable, consistent and widespread biodistribution of AAV9 vector throughout the brain and spinal cord regions in NHPs

 

  •  

Findings reaffirm the clinical potential of intrathecal administration as an effective, safe and minimally invasive delivery approach for broad targeting of the CNS that has potential for outpatient delivery in both children and adults

Anticipated Milestones

REVEAL Adolescent and Adult Trial

 

  •  

Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (low dose; n=2) expected in the first half of 2025

REVEAL Pediatric Trial

 

  •  

Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (high dose; n=2) expected in the first half of 2025

Third Quarter 2024 Financial Highlights

Research and Development Expenses: Research and development expenses were $14.9 million for the three months ended September 30, 2024, compared to $11.8 million for the three months ending September 30, 2023. The $3.1 million increase was driven by an $0.8 million increase in GMP batch activities during the three months ended September 30, 2024, which is representative of the intended commercial manufacturing process for TSHA-102 in Rett syndrome. Additionally, compensation for R&D employees increased as a result of higher headcount, and this was partially offset by lower consultant and contractor expenses.

General and Administrative Expenses: General and administrative expenses were $7.9 million for the three months ended September 30, 2024, compared to $8.6 million for the three months ended September 30, 2023. The decrease of $0.7 million was primarily due to the decrease in issuance costs allocated to the liability-classified 2023 pre-funded warrants associated with the August 2023 financing.

Net loss: Net loss for the three months ended September 30, 2024, was $25.5 million, or $0.1 per share, compared to a net loss of $117.1 million, or $0.93 per share, for the three months ended September 30, 2023. The reduction in net loss in 2024 was primarily due to a non-cash loss of $100.5 million recorded in 2023 from a change in fair value of warrant liability from the 2023 pre-funded warrants associated with the August 2023 financing.

Cash and cash equivalents: As of September 30, 2024, Taysha had $157.7 million in cash and cash equivalents. Taysha expects that its current cash resources will support planned operating expenses and capital requirements into the fourth quarter of 2026.

Conference Call and Webcast Information

Taysha management will hold a conference call and webcast today at 4:30 p.m. ET to review its financial and operating results and provide a corporate update. The dial-in number for the conference call is 877-407-0792 (U.S./Canada) or 201-689-8263 (international). The conference ID for all callers is 13748703. The live webcast and replay may be accessed by visiting Taysha’s website.

About TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, and our other product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the timing of initiating additional trials and reporting data from our clinical trials, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, the clinical potential of intrathecal administration and our current cash resources supporting our planned operating expenses and capital requirements into the fourth quarter of 2026. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2023, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Taysha Gene Therapies, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

 

     For the Three Months
Ended September 30,		     For the Nine Months
Ended September 30,		  
     2024     2023     2024     2023  

Revenue

    $ 1,788     $ 4,746     $ 6,311     $ 11,847  

Operating expenses:

         

Research and development

      14,946       11,791       50,676       44,096  

General and administrative

      7,902       8,589       22,324       23,328  

Impairment of long-lived assets

      4,838       616       4,838       616  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      27,686       20,996       77,838       68,040  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      (25,898 )      (16,250 )      (71,527 )      (56,193 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Other income (expense):

         

Change in fair value of warrant liability

      75       (100,456 )      (67 )      (100,456 ) 

Change in fair value of term loan

      (1,703 )      —        (4,035 )      —   

Interest income

      2,107       1,109       5,240       1,651  

Interest expense

      (24 )      (1,471 )      (80 )      (4,285 ) 

Other expense

      (81 )      (19 )      (44 )      (24 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other income (expense), net

      374       (100,837 )      1,014       (103,114 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (25,524 )    $ (117,087 )    $ (70,513 )    $ (159,307 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per common share, basic and diluted

    $ (0.10 )    $ (0.93 )    $ (0.29 )    $ (1.88 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average common shares outstanding, basic and diluted

      267,824,045       125,700,799       244,052,057       84,630,796  
  

 

 

    

 

 

    

 

 

    

 

 

  

Taysha Gene Therapies, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except share and per share data)

 

     September 30,
2024		     December 31,
2023		  

ASSETS

     

Current assets:

     

Cash and cash equivalents

    $  157,688     $  143,940  

Restricted cash

      449       449  

Prepaid expenses and other current assets

      3,418       3,479  

Assets held for sale

      —        2,000  
  

 

 

    

 

 

  

Total current assets

      161,555       149,868  
  

 

 

    

 

 

  

Restricted cash

      2,151       2,151  

Property, plant and equipment, net

      7,613       10,826  

Operating lease right-of-use assets

      8,678       9,582  

Other non-current assets

      220       304  
  

 

 

    

 

 

  

Total assets

    $ 180,217     $ 172,731  
  

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

Current liabilities:

     

Accounts payable

    $ 4,932     $ 6,366  

Accrued expenses and other current liabilities

      12,608       12,284  

Deferred revenue

      11,795       18,106  
  

 

 

    

 

 

  

Total current liabilities

      29,335       36,756  
  

 

 

    

 

 

  

Term loan, net

      42,971       40,508  

Operating lease liability, net of current portion

      17,751       18,953  

Other non-current liabilities

      1,363       1,577  
  

 

 

    

 

 

  

Total liabilities

      91,420       97,794  
  

 

 

    

 

 

  

Stockholders’ equity

     

Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2024 and December 31, 2023

      —        —   

Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 204,943,306 and 186,960,193 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

      2       2  

Additional paid-in capital

      674,643       587,942  

Accumulated other comprehensive income

      (2,328 )      —   

Accumulated deficit

      (583,520 )      (513,007 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      88,797       74,937  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 180,217     $ 172,731  
  

 

 

    

 

 

  

Company Contact:

Hayleigh Collins

Director, Head of Corporate Communications and Investor Relations

Taysha Gene Therapies, Inc.

hcollins@tayshagtx.com

Media Contact:

Carolyn Hawley

Inizio Evoke

Carolyn.hawley@inizioevoke.com

EX-101.SCH 3 tsha-20241113.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tsha-20241113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 tsha-20241113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Nov. 13, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001806310
Document Type 8-K
Document Period End Date Nov. 13, 2024
Entity Registrant Name Taysha Gene Therapies, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39536
Entity Tax Identification Number 84-3199512
Entity Address, Address Line One 3000 Pegasus Park Drive
Entity Address, Address Line Two Suite 1430
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75247
City Area Code (214)
Local Phone Number 612-0000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value
Trading Symbol TSHA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d877348d8k.htm tsha-20241113.xsd tsha-20241113_lab.xml tsha-20241113_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d877348d8k.htm": { "nsprefix": "tsha", "nsuri": "http://tayshagtx.com/20241113", "dts": { "inline": { "local": [ "d877348d8k.htm" ] }, "schema": { "local": [ "tsha-20241113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "tsha-20241113_lab.xml" ] }, "presentationLink": { "local": [ "tsha-20241113_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-11-13_to_2024-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d877348d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-11-13_to_2024-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d877348d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tayshagtx.com//20241113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-257205-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-257205-xbrl.zip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